Thanks in part to the solid advice, analysis and pharmaceutical industry experience demonstrated by Bridgehead, we secured a promising investment in a fast-growing European pharmaceutical company
23rd February 2012 Bridgehead International has recently completed a substantial commercial due diligence assignment for the global private equity firm, The Riverside Company. The target was a European pharmaceutical company with both marketed assets and a strong R&D pipeline.
William Jaworski, Senior Associate at Riverside commented, “Thanks in part to the solid advice, analysis and pharmaceutical industry experience demonstrated by Bridgehead, we secured a promising investment in a fast-growing European pharmaceutical company. The combination of Bridgehead’s in-depth understanding of the sector, coupled with their strong reporting and analytical skills, gave us everything we needed to know about the target’s product portfolio and its commercial capabilities and helped us find peace of mind regarding the strength of its development pipeline. We’ve been delighted with Bridgehead; the work was carried out on time, on budget and to an excellent standard. We would certainly use Bridgehead again for any future pharmaceutical consultancy work.”
Timothy Fitzgerald, CEO of Bridgehead International added, ‘Bridgehead’s expert team was able to provide a rapid, in depth assessment of the target’s business, ranging from financial projections, commercialisation strategy, market access and pricing through to the research and development portfolio. It is very satisfying to see that our advisory work has contributed to this investment and we wish the company and its investors every success for the future’.
Notes for Editors:
The Riverside Company
The Riverside Company is a global private equity firm focused on acquiring growing businesses valued at up to $200 million (€200 million in Europe). Since its founding in 1988, Riverside has invested in more than 275 transactions. The firm’s international portfolio includes more than 75 companies, and it has $3.2 billion/€2.5 billion in assets under management.
About Bridgehead International Ltd
Bridgehead International, a leading strategic healthcare consultancy, is a global provider of pricing, reimbursement, health economics and market access support and a preferred partner for many major companies in the pharmaceutical, medical device and diagnostic sectors.
Bridgehead provides a broad range of global market access services, including:
• Market access strategy
• Pricing assessment and strategy
• Payer research
• KOL, Physician and patient research
• Health economic assessment and modelling
• Core reimbursement dossiers
• Value propositions and messaging
• Product Lifecycle and portfolio strategy
• Market access due diligence
• Health Technology Assessments
Bridgehead also continues to be a respected leader in the due diligence space for initial public offerings, licensing and mergers and acquisitions.
With over 50 consultants and 60 associates in Europe, North America and Asia, Bridgehead offers a unique mix of scientific, technical, payer and professional consultancy experience and expertise.
In 2007 and 2011, Bridgehead was honoured with The Queen’s Award for Enterprise for outstanding achievement in international trade. The Award is the highest honour that can be bestowed upon a UK company and is the UK’s top award for business performance.
For further information on our services and capabilities please refer to http://www.bridgehead.com
Contacts at Bridgehead International:
Wendy Daunt, Marketing Executive
Tel: +44 (0) 1664 503 719
imothy A J Fitzgerald, CEO
Tel: +44 (0)1664 503 700
This press release was distributed by ResponseSource Press Release Wire on behalf of Bridgehead International in the following categories: Health, Business & Finance, Medical & Pharmaceutical, for more information visit https://pressreleasewire.responsesource.com/about.